Shunsuke Matsunaga and MIZUHO MEDY Co.,Ltd. cancelled the acquisition of 33.1% stake in Bio Matrix Research, Inc. from JCR Pharmaceuticals Co., Ltd..
September 25, 2015 at 05:00 am
Share
Shunsuke Matsunaga and MIZUHO MEDY Co.,Ltd. agreed to acquire 33.1% stake in Bio Matrix Research, Inc. from JCR Pharmaceuticals Co., Ltd. (TSE:4552) on September 25, 2014. Under the terms of the transaction, Shunsuke Matsunaga will acquire 5,000 shares and MIZUHO MEDY will acquire 1,500 shares. Post transaction, JCR Pharmaceuticals will hold 1,213 shares of Bio Matrix Research. The Board of JCR Pharmaceuticals resolved the transaction. The transaction is expected to close on October 31, 2014. The transaction is expected to have negligible effect on JCR Pharmaceuticals' financial results.
Shunsuke Matsunaga and MIZUHO MEDY Co.,Ltd. cancelled the acquisition of 33.1% stake in Bio Matrix Research, Inc. from JCR Pharmaceuticals Co., Ltd. (TSE:4552) on September 25, 2015.
MIZUHO MEDY CO., LTD. is a Japan-based company principally engaged in-vitro diagnostic pharmaceuticals business. The Company mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.